Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D
Executive Summary
Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.
You may also be interested in...
Imara Broadens Hematology Horizons With $63m Fundraising
Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II drug candidate into related blood disorders such as beta thalassemia.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Alzheimer's Rollercoaster: Azeliragon Misses Endpoints, But Responding Subgroup Identified
US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.